Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Seboral is a topical dermatological solution marketed by Pelpharma Handels, primarily indicated for the treatment of dandruff, seborrhea, and itchy scalp. It is a combination product containing **resorcinol** and **salicylic acid** as its primary active ingredients. Salicylic acid functions as a keratolytic agent by softening keratin and promoting the exfoliation of the stratum corneum, which helps clear scales associated with seborrheic dermatitis. Resorcinol complements this action with its own keratolytic and antiseptic properties, helping to reduce scalp irritation and manage microbial activity. The formulation is typically used as a hair tonic for direct application to the scalp to alleviate flaking and pruritus.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Seboral.